Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care.

Imke RedekerStefan MoustakisStyliani TsiamiXenofon BaraliakosIoana AndreicaBjoern BuehringJüergen Braun Uta Kiltz

Published in: Therapeutic advances in musculoskeletal disease (2023)

Our results indicated that three of four patients continue biosimilar ADA over 2 years with lower risks of withdrawal for male sex, older age, longer prior duration on originator ADA and originator ADA as first bDMARD.

Keyphrases

end stage renal disease
healthcare
newly diagnosed
rheumatoid arthritis
ejection fraction
oxidative stress
depressive symptoms
chronic kidney disease
chronic pain
replacement therapy
disease activity
community dwelling
ulcerative colitis